Prognostic impact of KMT2A-PTD in acute myeloid leukemia in the NGS era: a multicenter retrospective study.
The KMT2A gene is frequently altered in acute myeloid leukemia (AML). Our findings support routine PTD testing at diagnosis and the incorporation of KMT2A-PTD into prognostic risk stratification and clinical decision-making.
The KMT2A gene is frequently altered in acute myeloid leukemia (AML). Our findings support routine PTD testing at diagnosis and the incorporation of KMT2A-PTD into prognostic risk stratification and clinical decision-making.
What the study was
- Study design
- Retrospective study
- Sample size
- 585
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Annals of hematology
Why it surfaced
Relevant Hematologic malignancies study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.